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Abstract
Prolonged remission of hypercortisolism with steroidogenesis inhibitors has been described in patients with ectopic adrenocor-
ticotropic hormone (ACTH) syndrome. The anti-proliferative and pro-apoptotic effect of ketoconazole in human cancer cells was
previously suggested. The aim of this study was to explore the effects of ketoconazole on ACTH-producing and non-ACTH-
producing neuroendocrine tumor (NET) cell lines. The effects of ketoconazole alone, and in combination with somatostatin
analogs, were evaluated in two human cell lines: DMS-79 (ectopic ACTH-producing small cell lung carcinoma) and BON-1
(human pancreatic NET). Total DNAmeasurement, apoptosis, cell cycle, chromogranin A (CgA)/proopiomelanocortin (POMC)
expression by qRT-PCR, serotonin, CgA, and ACTH secretion assays were performed. In both cell lines, ketoconazole signif-
icantly suppressed cell growth and colony formation in a dose and time-dependent manner. The effect in DMS-79 was primarily
cytotoxic, while it was more apoptotic in BON-1 cells. Ketoconazole also induced increase in G0/G1 phase in both cell lines and
arrest in phase G2/M of BON-1 cells. Ketoconazole did not affect the secretion of serotonin, CgA, ACTH, or the mRNA
expression of CgA and POMC. Decreased serotonin secretion was observed after the combination treatment with pasireotide.
These results suggest a direct effect of ketoconazole on cell proliferation, apoptosis, and cell cycle in both ACTH- and non-
ACTH-producing NET cells.
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Background
Neuroendocrine tumors (NETs) are a heterogeneous family of
neoplasms derived from neuroendocrine cells with a wide
spectrum of clinical behavior [1]. NETs can occur sporadically
or as a result of hereditary predisposition syndromes [2]. Their
capacity to secrete peptide hormones divides them in function-
ing and non-functioning tumors [1].
One of the most uncommonly secreted hormones is adreno-
corticotropic hormone (ACTH) [3, 4], resulting in
hypercortisolism and ectopic ACTH syndrome (EAS). EAS is
a form of Cushing syndrome (CS) associated with overt malig-
nancies or indolent tumors, including neuroendocrine tumors of
the lungs, thymus, and gastrointestinal tract [3–6]. The manage-
ment of patients with EAS requires strict control of
hypercortisolism as soon as the diagnosis is established, in order
to avoid related complications [3, 7, 8]. In EAS patients, initial
resection of the primary lesion is the first-line treatment option.
However, in some cases, surgery is not possible or successful
and in other cases, the source of ectopic ACTH is not identified
[8, 9]. For these patients, medical treatment with steroidogenesis
inhibitors including ketoconazole and bilateral adrenalectomy
represents alternative therapeutic options [10–12].
Ketoconazole is widely used for medical treatment of CS
and can improve clinical signs, symptoms, and comorbidities
[10]. Ketoconazole impairs adrenal and gonadal steroidogen-
esis by inhibiting side-chain cleavage, 17,20-lyase, and 11-β
hydroxylase enzymes [13]. Because cortisol production is
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often very high in EAS, ketoconazole may be less effective in
controlling hypercortisolism in EAS patients compared with
Cushing disease patients [10]. However, the drug could exert
additive effects in the control of patients with severe
hypercortisolemia [13]. A direct effect of ketoconazole on
tumoral ACTH secretion has been suggested [14, 15], since
its use in some EAS cases has been followed by prolonged
remission of hypercortisolemia [14–16]. Ketoconazole also
reduces ACTH secretion from thymic tumor cells in culture
[17], suggesting a dual (direct/indirect) action of ketoconazole
on EAS tumors.
Some ectopic ACTH-producing tumors express somato-
statin receptors, suggesting a putative role of somatostatin
analogs (SSA) for reducing ACTH production. Octreotide in-
hibits the release of ACTH in some patients with Nelson’s
syndrome and EAS from metastatic gastroenteropancreatic-
NETs, small cell lung carcinoma, carcinoids, and medullary
thyroid carcinoma [18–20]. However, in clinical practice, the
effect of SSA is limited, but their use has been suggested when
other inhibitors of steroidogenesis fail or when parenteral ad-
ministration is required [21].
Despite the development of new therapeutic options in
NETs, treatment strategies are still limited. As such, it is nec-
essary to develop novel therapeutic strategies. In this scenario,
we aimed to evaluate additional, not previously described
in vitro effects of ketoconazole as monotherapy, as well as in
combination with SSA on proliferation and hormonal secre-
tion of ACTH-producing and non-ACTH-producing neuroen-
docrine tumor cell lines, in order to determine potential off
target effects of ketoconazole on NET cells.
Materials and Methods
Cell Culture
We used the human small cell lung carcinoma cell line DMS-
79 and the human pancreatic neuroendocrine tumor cell line
BON-1. The cell line DMS-79 (ATCC-CRL-2049™,
Manassas, VA, USA) was isolated from pleural fluid of an
ACTH-producing small cell lung carcinoma. The BON-1 cell
line was a kind gift of Dr. Townsend (The University of Texas
Medical Branch, Galveston, TX, USA) and was established
from a lymph node metastasis of a human functional pancre-
atic neuroendocrine tumor. Both cell lines were routinely cul-
tured in 75-cm2 flasks (Greiner bio-one, The Netherlands) at
37 °C in a 5% CO2 incubator.
BON-1 cells were cultured in DMEM/F12 (GIBCO Biocult
Europe, Breda, The Netherlands) containing 10% FCS, L-glu-
tamine, fungizone (0.5 mg/L), and penicillin (100 U/mL)
(Bristol-Myers Squibb, Woerden, The Netherlands). Cells were
harvested with trypsin (0.05%)–EDTA (0.53 mM) and resus-
pended in culturemedium. Cell viability always exceeded 85%.
For the serotonin and chromogranin measurements, BON-1
cells were cultured in DMEM/F12 (GIBCO Biocult Europe,
Breda, The Netherlands) containing 0.1% BSA, L-glutamine,
fungizone (0.5 mg/L), and penicillin (105U/L) (Bristol-Myers
Squibb, Woerden, The Netherlands) after an initial incubation
period of 24 h in 10% FCS to allow the cells to attach.
DMS-79 cells were cultured in RPMI 1640 (GIBCO
Biocult Europe, Breda, The Netherlands) containing 10%
heat-inactivated (Hi)-FCS, L-glutamine, and penicillin (105
U/L) (Bristol-Myers Squibb, Woerden, The Netherlands).
Cells were harvested with pipetting and cell viability always
exceeded 80%. All cell line proliferation experiments were
performed at least four times.
Drugs and Reagents
Ketoconazole was purchased from Sigma-Aldrich (Zwijndrecht,
The Netherlands) and dissolved in ethanol as a 10−2 M stock
solution (stored at − 20 °C) and diluted in ethanol prior to use.
We tested concentrations ranging between 10−5 and 10−7 M in
BON-1 cells and concentrations ranging between 5 × 10−5 and
5 × 10−7M in DMS-79 cells. Control wells were treated only
with vehicle only (ethanol). We used different concentrations
for both cell lines because the cell lines showed a different
sensitivity to ketoconazole in pilot experiments (not shown).
For both cell lines, all experiments included the clinically rele-
vant concentrations of ketoconazole.
Octreotide and pasireotide were obtained from Novartis
Pharma (Basel, Switzerland) and diluted in medium until a
final concentration of 10−8 M.
Cell Proliferation Assay
Measurement of Total DNA Content (Measure of Total Cell
Number)
Cells were plated in 1 mL medium in 24-well plates at a
density necessary to obtain a 65–70% cell confluence in the
control groups at the end of the experiment (50,000 cells/well
for 3 days and 10,000 cells/well for 7 days in BON-1 cells;
150,000 cells/well for 3 days and 75,000 cells/well for 7 days
in DMS-79 cells). Twenty-four hours later, the medium was
refreshed and increasing concentrations of ketoconazole,
alone or combined with SSA, were added to the cells.
After 3 and 7 days of treatment, the cells were harvested for
DNA measurement, as a measure of cell number. For 7 days,
treatment medium and drugs were refreshed at day 3. The
procedure for the DNA measurement has been previously
described in detail [22, 23]. Briefly, the cells were treated with
150 μL of ammonia solution (1 mol/L)-Triton X 100 (0.2%
v/v) for 15 min. Thereafter, sonification was performed
(Soniprep 150; amplitude 1400 μm). Subsequently, 1 mL of
assay buffer (100 mM NaCl, 100 mM EDTA, 10 mM Tris;
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pH 7.0) was added. For DNA measurement, 20 μL of the
solution was mixed with 200 μL of Hoechst dye H33258
solution (1 μg/mL). Fluorescence was measured with the ex-
citation and emission wavelengths set at 350 and 455 nM
respectively. The fluorescence of experimental samples was
referenced to a standard curve of calf thymus DNA (type II, no
D-3636; Sigma-Aldrich (Zwijndrecht, The Netherlands).
Soft Agar Colony Forming Assay
The effect of ketoconazole on colony formation was evaluated
using a soft agar colony forming assay. The method was ac-
cording to a previously described protocol [24]. The number
of cells plated in the upper layer of 0.3% agar (Sigma Aldrich)
was 15,000 for DMS-79 and 5000 for BON-1. After 7 and
14 days, 1 mL of medium without or with increasing concen-
trations of ketoconazole (range between 5 × 10−5 and 10−6 M)
was added. Adequate colony formation was achieved around
day 21. At this time point, the cells were stained with 200 μL
nitroblue tetrazolium chloride solution (1 mg/mL; Sigma) per
well and overnight incubation at 37 °C. Once colonies were
stained, photomicrographs were taken with aMultimage Light
Cabinet (Alpha Innotech Corporation, USA). Analysis of col-
ony number and size was performed using the software pro-
gram ImageJ. Only colonies with a size ≥ 75 μM were
analyzed.
Quantitative RT-PCR
mRNA expression of chromoganin A (CgA) in BON-1 cells,
proopiomelanocortin (POMC) in DMS-79 cells, and somato-
statin receptors (SST1, SST2, SST3, SST5) in both cell lines
was evaluated by quantitative RT-PCR. We used a previously
described method [25]. In short, poly(A+) mRNAwas isolated
using Dynabeads Oligo (Deoxythymidine)25 (Dynal AS,
Oslo, Norway). The poly(A+) mRNA was eluted in H2O
(65 °C) twice for 2 min each and used for cDNA synthesis
in a Tris buffer [50 mm Tris-HCl (pH 8.3), 100 mm KCl,
4 mm dithiothreitol, and 10 mmMgCl2] with 10 U ribonucle-
ase inhibitor, 2 U avian myeloblastosis virus Super Reverse
Transcriptase, and 1 mm of each deoxynucleotide triphos-
phate in a final volume of 40 μL. This mixture was incubated
for 1 h at 42 °C, and the resulting cDNAwas diluted fivefold
in 160 μL sterile H20. The total reaction volume (25 μL)
consisted of 10 μL cDNA and 15 μL TaqMan Universal
PCR Mastermix (Applied Biosystems, Branchburg, NJ).
Primers were used at final concentration of 300 nm and probe
at 200 nm. Real-time qPCR was performed in 96-well optical
plates with the TaqMan Gold nuclease assay (Applied
Biosystems, Roche) and the ABI Prism 7700 Sequence
Detection System (PerkinElmer, Foster City, CA). After two
initial heating steps at 50 °C (2 min) and 95 °C (10 min),
samples were subjected to 40 cycles of denaturation at 95 °C
(15 s) and annealing at 60 °C (60 s). All samples were assayed
in duplicate. Dilution curves were constructed to calculate
PCR efficiencies (E) for every primer-probe set [26]. To ex-
clude genomic DNA contamination in the RNA, the cDNA
reactions were also performed without reverse transcriptase
and amplified with each primer pair. To exclude contamina-
tion of the PCRmixtures, the reactions were also performed in
the absence of a cDNA template.
CgA and POMC mRNA were normalized to the house-
keeping genes HPRT1, beta-glucuronidase (GUSB), and
beta-actine (ACTB/ACTB) expression levels using the method
of Vandesompele [27]; somatostatin receptors were normal-
ized against HPRT1. CgA, POMC, GUSB, ACTB primer/
probes were purchased from Thermo Fisher Scientific,
The Netherlands, while the used sequence of somatostatin
receptors and HPRT1 has been previously described [28].
PCR efficiencies were as follows: CgA: 1.95, POMC: 1.92,
SST1: 2, SST2: 1.91, SST3: 1.92, SST5: 1.92, HPRT1: 1.91,
ACTB: 1.91, GUSB: 2. The relative expression of genes was
calculated using the comparative threshold method, 2−ΔC1
[29], after efficiency correction [30] of target and reference
gene transcripts (HPRT, GUS-B, ACTB). All experiments
were performed at least twice with four replicates.
Cell Cycle Assay—Apoptosis Analysis
Cells were plated in 12-well plates at the density neces-
sary to obtain a 65–70% cell confluence in the control
groups at the end of the experiment. Twenty-four hours
later, ketoconazole was added to wells in triplicate. In
each cell line, the effects of ketoconazole on cell cycle
were tested in three concentrations (5 × 10−6, 10−6, and
5 × 10−5 M in DMS-79; 10−6, 5 × 10−6, and 10−5 M in
BON-1 cells) on cell proliferation after 7 days of treat-
ment. We evaluated the effects of the compounds on cell
cycle and apoptosis after 72 h of treatment. Following
treatment, cells were harvested and collected by centrifu-
gation. For cell cycle, cells were fixed in 70% ice-cold
ethanol, followed by an overnight incubation at − 20 °C.
Samples were measured using the Muse™ cell cycle kit
(Merck) and prepared according to the manufacturer’s
protocol. For apoptosis measurement, cells were resus-
pended in 100 μL PBS/1% FCS, according to the proto-
col provided by the manufacturer. A commercially avail-
able kit was used (Muse™ annexin V dead cell). All
measurements were performed using the Muse® Cell
Analyzer (Merck). Apoptosis was measured using a com-
mercially available ELISA (Cell Death Detection ELISA
Plus, Roche, The Netherlands) according to the manufac-
turer’s protocol. Lactate dehydrogenase LDH release was
measured using a kit (pierce LDH cytotoxicity assay kit,
Thermo scientific, The Netherlands) and samples were
treated according to the protocol provided by the
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manufacturer. All experiments were performed at least
three times using three replicates.
ACTH Secretion Assay
In DMS-79 cells, we evaluated the effects of ketoconazole
alone and in combination with octreotide/pasireotide on
ACTH secretion after 3 and 7 days of treatment. Cells were
plated in 24-well plates and treated as described earlier for the
cell proliferation assay. The experiment was performed twice.
ACTH levels were determined using a chemiluminescent
immunometric assay in an IMMULITE® 2000 system.
ACTH secretion values were normalized for cell amount per
well (DNA). The sensitivity of this assay ranged between 1.1
and 270 pmol/L. Untreated control values were within this
range. All experiments were performed at least two times
using four replicates.
Chromogranin A and Serotonin Secretion Assay
BON-1 cells were plated in 24-well plates using a medium
containing 0.1% BSA, and treated as described earlier for
the cell proliferation assay. Medium was collected from
each well, to samples for the serotonin ELISA ascorbic
acid was added (final concentration 0.1%). A commercial-
ly available human chromogranin An ELISA kit (Epitope
diagnostics Inc., San Diego CA, USA) and a serotonin
high sensitive ELISA (IBL International, Hamburg
Germany) were used following the manufacturer’s instruc-
tions. The DNA content per well was used to correct both
serotonin and CgA absolute values. All experiments were
performed at least two times using four replicates.
Statistical Analysis
For the statistical analysis, statistical software of GraphPad
Prism version 5 (GraphPhad Software, San Diego, CA)
was used. Between-group comparisons were analyzed by
the Mann–Whitney U test (nonparametric data), or the
Kruskal–Wallis test (nonparametric data, when we com-
pared more than two groups). Differences were taken to
be statistically significant at p < 0.05. Results are expressed
as mean ± S.E.M. and percentages. Log transformation was
used for calculating the IC50.
Results
Effects of Ketoconazole
The growth inhibitory effects of ketoconazole onDMS-79 and
BON-1 cells growth are dose- and time-dependent (Fig. 1).
DMS-79 cells (Fig. 1a) are slightly less sensitive to ke-
toconazole compared with BON-1 cells (Fig. 1b). The ef-
fects of ketoconazole ranged between 47.20% inhibition
(p < 0.0001) at the maximal dose (5 × 10−5 M) and 10.32%
(p < 0.05) at the dose of 5 × 10−6M after 3 days of treatment.
After 7 days, the effect of ketoconazole increased to 87.3%,
46.3%, and 29.8% with ketoconazole 5 × 10−5 M, 10−5 M,
and 5 × 10−6 M respectively (p < 0.0001). The IC50 after
7 days of incubation was 1.5 × 10−5 M (95%CI 1.0 × 10−5–
2.3 × 10−5 M). Ketoconazole (10−5 M and 5 × 10−6 M) sig-
nificantly inhibited the number (90.73–44.41%, respective-
ly) and the size (33.95–33.30%, respectively) of the colo-
nies in agar (Fig. 2a). 5 × 10−5 M ketoconazole completely
abolished DMS-79 colony formation.
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Fig. 1 Dose- and time-dependent effect of ketoconazole after 3 and 7 days
of treatment. a Effect on cell growth (DNA) in DMS-79 cells. b Effect on
cell growth in BON-1 cells. Ketoconazole significantly suppressed cell
growth in a dose- and time-dependent manner. Solid and dotted black
lines represent DNA content in percentage after 3 (__) and 7 days (…)
respectively. The gray vertical dotted line represents the clinically rele-
vant plasmatic concentration of ketoconazole. Values represent mean ±
SEM and are shown as a percentage of control. c Control
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In BON-1 cells, the inhibitory effect of ketoconazole
ranged between 41.03% at the maximal dose (10−5 M;
p < 0.0001) and 19.1% at a dose of 5 × 10−6 M (p < 0.01) after
3 days of treatment (Fig. 1b). After 7 days, the growth inhib-
itory effect increased to 95.23% and 74.82% with ketocona-
zole 10−5 M and 5 × 10−6 M respectively (p < 0.0001)
(Fig. 1b). The IC50 after 7 days of incubation was 7.7 ×
10−6 M (95%CI 3.8 × 10−6–1.6 × 10−5 M). Ketoconazole
(10−5 M and 5 × 10−6 M) significantly inhibited the number
(88.31–52.19%, respectively). Only ketoconazole 10−5 M de-
creased the colony size of this cell line in agar (21.2%)
(Fig. 2b). Ketoconazole 5 × 10−5 M completely abolished
BON-1 colony formation.
Effect of Ketoconazole in Combination
with Octreotide and Pasireotide
In DMS-79 cells, neither pasireotide nor octreotide inhibited
cell growth (Fig. 3a and b, left panels). In combination with
pasireotide or octreotide, ketoconazole exerted a similar
growth inhibitory effect compared with the effect of ketoco-
nazole alone (Fig. 3a and b, right panels).
In BON-1 cells, octreotide slightly decreased cell growth
by 9.4% (p < 0.05) after 3 days of treatment only (Fig. 3c, left
panel), whereas pasireotide slightly inhibited cell growth by
13.5% (p < 0.01) at day 7 (Fig. 3d, left panel). In combination
with pasireotide and octreotide, ketoconazole appeared slight-
ly less effective at high dose ketoconazole (Fig. 3c and d, right
panels).
Somatostatin Receptor Subtype Expression
The relative mRNA expression of somatostatin receptor sub-
types was evaluated in both cell lines (Supplementary
Figure 1). SST1 and SST5 expression in DMS-79 was lower
compared with BON-1 cells. Rank order of expression in
DMS-79 was SST1 = SST2 > SST3 > SST5 and for BON-1
SST1 > SST5> > SST2 > SST3.
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Fig. 2 Dose-dependent effect of ketoconazole on colony formation. a
Colony number, b colony size of DMS-79 cells. d Colony number, e
colony size of BON-1 cells. Ketoconazole significantly suppressed the
number and size of colonies in both cell lines. Right panels (c, f) show
representative images of the colonies treated with 5 × 10−6 M
ketoconazole after staining with nitroblue tetrazolium chloride and anal-
ysis of images with ImageJ. Values represent mean ± SEM and are shown
as a percentage of vehicle-treated control. Asterisks *, p < 0.05. ND non-
detectable
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Apoptosis Assays
In DMS-79 cell line, the highest ketoconazole concentra-
tion evaluated (5 × 10−5 M) induced a significant increase
in dead cells (p < 0.001) with a slight increase in late apo-
ptosis (p < 0.05) and decrease in living cells (p < 0.01;
Fig. 4a). Moreover, the LDH/DNA ratio increased after
3 days of treatment with ketoconazole 5 × 10−5 M and
10−5 M (Fig. 4c left panel; p < 0.001; p < 0.05 respectively),
while the apoptosis/DNA ratio increased only with the
highest concentration tested (Fig. 4c, right panel;
p < 0.001).
In BON-1 cells, the highest ketoconazole concentration
tested (10−5 M) induced a significant increase in early
apoptosis, as well as late apoptosis (p < 0.0001).
Consequently, the percentage of live and dead cells de-
creased (Fig. 4b). In order to confirm these results, the
percentage of LDH release was determined. After 3 days
of treatment with ketoconazole 10−5 M, LDH increased by
approximately 50%, combined with a threefold increase in
apoptosis/DNA ratio (p < 0.05; Fig. 4d).
Cell Cycle Progression
In DMS-79, a slight statistically significant G0/G1-phase
increase was observed with the highest ketoconazole
concentration tested (p < 0.01), without having a statisti-
cal significant effect on the other cell cycle phases
(Fig. 5a).
In BON-1 cell line, ketoconazole (10−5–5 × 10−6M) induced
a statistical significant G0/G1-phase increase (p < 0.0001,
p < 0.01 respectively), accompanied by a decrease in G2-
phase (p < 0.0001; Fig. 5b).
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Fig. 3 Dose- and time-dependent effects of the combination treatment
with ketoconazole and somatostatin analogs on cell proliferation after 3
and 7 days of treatment. a, b Percentage of control of cell growth in DMS-
79 cells after 3 and 7 days respectively; c, d percentage of control of cell
growth in BON-1 cells after 3 and 7 days respectively. The bar graphs
represent the effect of SSA alone (octreotide and pasireotide, both at
10−8 M), compared with untreated control. The line graphs represent
the effect of ketoconazole alone, or in combination with a fixed dose
(10−8 M) of SSA (set at 100%). Ketoconazole significantly suppressed
DNA content in a dose and time-dependent manner, a slightly decreased
effect was observed after a combination with somatostatin analogs. Lines
represent DNA content as a percentage after incubation with ketocona-
zole alone (solid line), ketoconazole-octreotide (dashed line), and
ketoconazole-pasireotide (dotted line) respectively. Values represent
mean ± SEM and are shown as a percentage of control. C, control.
Asterisks *p < 0.05; ***p < 0.0001 compared with untreated controls
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Chromogranin A and POMC Expression
Ketoconazole did not have a statistically significant effect onPOMC
mRNA expression in DMS cells (Supplemental Figure 2A) nor on
CgAmRNA expression in BON-1 cells (Supplemental Figure 2B)
after 3 days of treatment at any of the doses tested.
ACTH and Serotonin Secretion
Effects on ACTH secretion were evaluated in DMS-79 cells.
When corrected for the effect of ketoconazole on total cell
number (ACTH/DNA ratio), ketoconazole inhibited the re-
lease of ACTH after 3 days of treatment only with the highest
tested concentration of ketoconazole (5 × 10–5 M) (Fig. 6a).
ACTH was undetectable after 7 days of treatment with keto-
conazole 5 × 10−5 M (Fig. 6b), likely due to the very potent
lowering of cell number. When combined with pasireotide, a
similar pattern of inhibition of ACTH release was observed
(Fig. 6a and b, middle panels). Octreotide alone slightly
inhibited ACTH release after 7 days of incubation. In combi-
nation with ketoconazole, only in the presence of the highest
concentration of ketoconazole ACTH concentrations were
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Fig. 4 Dose-dependent effect of ketoconazole on apoptosis after 3 days
of treatment. a DMS-79 cells: the highest ketoconazole concentration
tested (5 × 10−5 M) induced a significant increase in dead cells and late
apoptosis. b BON-1 cells: the highest ketoconazole concentration tested
(10−5M) induced a significant increase in early apoptosis as well as in late
apoptosis. Apoptosis (DNA fragmentation) and LDH release after 3 days
of treatment in DMS-79 cells (c) and BON-1 cells (d). The highest keto-
conazole concentration tested increased apoptosis as well as LDH levels
in both cell lines. Values represent mean ± SEM and are expressed as
percentage of control of the apoptosis/DNA ratio and LDH/DNA ratio.
Asterisks *p < 0.05; **p < 0.01, ***p < 0.001 compared with untreated
controls
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undetectable (Fig. 6a and b, right panels). Supplementary
Figure 3 shows the effect of ketoconazole on ACTH concen-
trations in the medium, not corrected for the effect of ketoco-
nazole on cell number. It was not possible to measure seroto-
nin secretion in BON-1 cells cultured in medium with FCS,
due to a matrix effect in the serotonin assay (data not shown).
In order to determine the effect of ketoconazole on serotonin
secretion, BON-1 cells were cultured in medium containing
0.1% BSA. A dose-dependent inhibitory effect of ketocona-
zole on the proliferation of BON-1 cell line in 0.1% BSA
medium was observed (Supplementary Figure 4A). The abso-
lute production of serotonin decreased when cells were treated
with high doses of ketoconazole, especially when combined
with pasireotide, while no additional effect was observed
when combined with octreotide (Supplementary Figure 4B).
After calculating the serotonin/DNA ratio (to correct for the
effect of ketoconazole on cell number), ketoconazole, and its
combination with octreotide, did not have a statistical signif-
icant effect on serotonin secretion, while pasireotide decreased
its production by 45% (Fig. 7a).
The absolute production of CgA in BON-1 cells decreased
when cells were treated with high doses of ketoconazole
(10−5–5 × 10−6 M). This effect remained when combined with
pasireotide and octreotide (Supplementary Figure 4C). After
calculating the CgA/DNA ratio, no statistically significant ef-
fect was observed after 3 days of treatment with ketoconazole
alone or in combination with SSA (Fig. 7b).
Discussion
In the present study, we evaluated the direct effects of ketoco-
nazole in ACTH-producing and non-ACTH-producing NET
cell lines. We examined effects on proliferation, mRNA ex-
pression, and secretion by ketoconazole as monotherapy, as
well as in combination with SSA, the latter representing the
recommended first-line therapy in non-functioning/function-
ing progressive G1/G2 NETs [31]. Our results revealed a par-
ticular effect of ketoconazole on proliferation, cell cycle,
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Fig. 5 Dose-dependent effect of ketoconazole on cell cycle progression
in DMS-79 cells (a) and BON-1 cells (b) after 3 days of treatment. In
DMS-79 cells, ketoconazole (5 × 10−5 M) induced a slight but significant
G1-phase increase. In BON-1 cells, ketoconazole (10−5–5 × 10−6 M) in-
duced G1-phase increase and decrease in G2-phase. Asterisks *p < 0.05;
**p < 0.01, ***p < 0.001 compared with untreated controls
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apoptosis, and mRNA expression, which was slightly differ-
ent between the evaluated NET cell lines.
Ketoconazole is widely used for medical treatment of CS
[10]. Apart from its inhibitory effect on steroidogenesis, keto-
conazole may have direct antitumor effects as EAS cases have
been described in which temporarily treatment with ketocona-
zole was followed by prolonged remission of hypercortisolemia
[16]. For this reason, previously non-described off target
in vitro effects of ketoconazole were evaluated in this study.
While the evaluation of the effects of ketoconazole was the
primary aim of this study, its combination with SSA was
assessed due to their applicability in the clinical practice.
SSAs are first-line therapy in functionally active NETs, includ-
ing those associated with the carcinoid syndrome and function-
al pancreatic neuroendocrine tumors (PNETs) [32, 33]. We
used two different SSA based on the fact that their anti-
proliferative effect may depend on the expression level and type
of SSTs in the tumor [34]. Since the affinity of pasireotide for
SST5 is 30–40-fold higher when compared with octreotide [35],
both SSAwere selected for this study.
In our study, we included clinically relevant concentrations
of ketoconazole, based on previous results in humans. Several
studies report serum ketoconazole levels of 3.6 μg/mL and
6.5 μg/mL after the administration of 200 and 400 mg of
ketoconazole respectively [36]. The continuous administra-
tion of 400 mg/8 h resulted in serum ketoconazole levels of
2–9 μg/mL [37]. Several effects in this study on the NET cell
lines have been achieved with these ketoconazole concentra-
tions (5.3 μg/mL ketoconazole corresponds to 10−5 M).
Sharma and Nieman described four patients with EASwith
prolonged remission of hypercortisolism following treatment
with ketoconazole alone or in combination with metyrapone
and/or mitotane. In one patient, this was accompanied by in-
creased ACTH levels indicating a direct, sustained suppres-
sive effect on the adrenal cortex. In two other patients, how-
ever, ACTH levels were normal to low suggesting a direct
effect of ketoconazole on ectopic ACTH-producing tumor
cells [16]. In this sense, we observed decreased cell growth
in both ACTH-producing and non-ACTH-producing NET
cell lines, when exposed to ketoconazole in pharmacological
concentrations (10−5–5 × 10−6 M). Importantly, DMS-79 cells
are slightly less sensitive than BON-1 cells, and required
higher doses for obtaining similar inhibitory effects in mono-
layer cultures. In the colony forming assay ketoconazole at a
dose between 10−5 and 5 × 10−6 M induced similar cytotoxic
effects in both cell lines.
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Fig. 6 Dose-dependent effect of ketoconazole on ACTH secretion in
DMS-79 cells after 3 (a) and 7 days (b) of treatment. Ketoconazole
(5 × 10−5 M) significantly decreased ACTH secretion (corrected for cell
number) after 3 days but not after 7 days of treatment, as well as its
combination with pasireotide; octreotide decreased the ACTH/DNA ratio
after 7 days. ACTH secretion was normalized to the effect on cell number
(ratio ACTH/DNA). ND non-detectable ACTH. Asterisks *p < 0.05;
**p < 0.01; ***p < 0.001, compared with untreated controls
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The mechanism of action of ketoconazole seems to be dif-
ferent in both cell lines. In BON-1 cells, ketoconazole has an
apoptotic effect (especially increasing early apoptosis), where-
as in DMS-79 cell line, the effect seems to be more cytotoxic.
Previous reports have described a cytotoxic effect of
ketoconazole in prostate cancer, adrenal cancer, and male
metastatic breast cancer cell lines with a dose- and time-
dependent pattern at clinically feasible concentrations
[38]. In addition, it has been shown that ketoconazole
decreased tumor surface area and tumor colonies in liver
metastasis of human pancreatic adenocarcinoma in ani-
mal models [39]. This antitumor action of ketoconazole
is further confirmed in our study, in which ketoconazole
inhibited not only the number of colonies, but also the
colony size. Due to its androgen lowering properties,
ketoconazole is also evaluated as a potential treatment
in other neoplasms such as prostate cancer [37]. In these
patients, the drug is administered at high doses (400 mg/
8 h/day), in combination with hydrocortisone [40].
Approximately, 27–60% of treated patients show up to
50% decrease in prostate antigen without receiving con-
comitant anti-androgen treatment. In addition, those
patients that respond to treatment and do not have met-
astatic disease showed prolonged responses even after
7 years [40, 41]. Related to this, preliminary reports have
suggested that the use of ketoconazole (600 mg/day)
combined with docetaxel has a significant antitumor ef-
fect in castration-resistant prostate cancer patients [42].
The cell growth inhibitory effects observed in our study
suggest that an off target direct antitumor action of ke-
toconazole may be involved in the sustained remission
which is sometimes observed in patients with ectopic
ACTH secreting NET that are treated with this drug [16].
Differences observed in sensitivity to ketoconazole be-
tween both cell lines may be related to the heterogeneity of
NETs [2]. Tumor heterogeneity may explain different clinical
responses to therapeutic options, including SSA and peptide
receptor radionuclide therapy, as well as molecular targeted
therapies [43–45]. In this sense, tumor heterogeneity affects
clinical management and decision-making in NETs [46].
Additionally, tumor response may differ according to the pri-
mary tumor localization and tumor load [47]. DMS-79 and
BON-1 are lung- and pancreas-derived cell lines, respectively.
Furthermore, tumor cell characteristics were different; BON-1
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Fig. 7 Dose-dependent effect of ketoconazole on serotonin (a) and
chromogranin A (b) secretion in BON-1 cells after 3 days of treatment.
In BON-1 cells, pasireotide reduced serotonin secretion; ketoconazole
alone or in combination with octreotide did not significantly affected
serotonin secretion. No statistically significant effect was observed on
CgA secretion after treating cells with ketoconazole alone or in combina-
tion with pasireotide or octreotide. Serotonin and CgA secretion were
normalized to the effect on cell number (ratio serotonin/DNA; ratio
CgA/DNA). Asterisks ***p < 0.001, compared with untreated controls
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cells attach to the culture plate surface, while DMS-79 grow in
suspension and form small aggregates. Moreover, we observed
a different somatostatin receptor expression pattern between
both cell lines. Similar findings may be observed in other func-
tional pathways that could also explain differences in the re-
sponse of both cell lines [48]. Importantly, in the colony forma-
tion assay, DMS-79 cells were similarly sensitive to the effects
of ketoconazole compared with BON-1 cells.
Focusing on treatment of NETs, it is already known that
SSA have antitumor effects in patients with NETand that they
are useful for symptoms control and disease stabilization [31,
49, 50]. Despite this, in vitro findings reveal a weak effect of
SSA on cell proliferation [48]. In our study, we observed only
a very weak anti-proliferative effect of octreotide after 3 days
and of pasireotide after 7 days of treatment, which is concor-
dant with reports in literature [31]. The response to pasireotide
after 7 days in BON-1 cells is probably related to the high
expression of SST1 and SST5 receptors in this cell line.
Interestingly, in BON-1 cells, the effectiveness of ketocona-
zole in combination with SSA on cell proliferation seems to be
slightly decreased.
Our results on apoptosis are concordant with previous stud-
ies in other cell line models. Ho et al. reported apoptosis in-
duced by ketoconazole in human colorectal and hepatocellular
carcinoma cell lines through the p53 pathway (increased bax
and decreased bcl-2 gene products) with minimal ketocona-
zole concentrations of 5 μg/mL [51]. Similarly, Won et al.
suggested that ketoconazole could increase apoptosis and de-
crease cell viability in rats through reactive oxygen species
(ROS) in rat cardiomyocytes [52]. Some other signaling
routes have been proposed for explaining the apoptotic effect
of ketoconazole, including the JNK phosphorylation in human
osteosarcoma [53]. Ketoconazole, when combined with
terfenadine, seems to potentiate the inhibition of cytochrome
p450 3A4 in human cancer cell lines [54].
When evaluating cell cycle, published results are contra-
dictory. Forgue-Lafitte et al. reported decreased cell number in
S phase and a corresponding increase in G0-G1 phases in
colon cancer cells treated with ketoconazole [55]. In contrast,
Chen et al. described G0/G1 arrest in human colorectal and
hepatocellular cell lines [56]. However, in our study, we ob-
served in both cell lines a significant increase in G0/G1 phase,
which was accompanied with an arrest of G2/M phases in
BON-1 cells. These results suggest that ketoconazole may
have a differential mechanism of action in different tumor cell
lines.
When analyzing secretion, ketoconazole did not affect se-
rotonin secretion, but the effect of pasireotide on serotonin
production is relevant and stable after its combination with
ketoconazole, suggesting a therapeutic indication for
pasireotide in (a subset of) patients with carcinoid syndrome
or functioning NETs with liver metastasis, refractory to clas-
sical SSA. Interestingly, pasireotide had no effect on CgA
secretion, suggesting that serotonin may be a better marker
of secretion. Pasireotide has a higher binding affinity for
SST1, SST3, and SST5 when compared with octreotide, as
well as a slightly lower affinity for SST2 [57]. Moreover, as
we did not observe any effect of ketoconazole alone or com-
bined with SSA on CgA secretion after correcting for its effect
on cell number, it is likely that CgA is related to tumor growth
and less to tumor secretion capacity [58].
Changes on hormone secretion by ketoconazole have been
previously described. Ketoconazole increases the spontaneous
and stimulated release of prolactin in normal and tumoral rat
pituitary cells [59], and decreases the ACTH production in
human thymic carcinoid cells [17]. It has been also hypothe-
sized that ketoconazole could affect tumoral ACTH and cyclic
ACTH secretion in vivo [16]. In our study, however, we did
not observe a direct inhibitory effect of clinically feasible con-
centrations of ketoconazole on ACTH production by DMS-79
cells (corrected for the effect of ketoconazole on cell growth),
suggesting that the effect of ketoconazole is primarily cyto-
toxic. The absence of an effect on ACTH production may also
be reflected by the fact that ketoconazole did not affect POMC
mRNA expression.
In summary, this study provides a primary comprehensive
mapping of the effect of ketoconazole on NET cell lines, sug-
gesting a potential effect of ketoconazole on cell proliferation,
apoptosis, and cell cycle. This antitumor effect appears not
tumor cell type–specific, since it was observed in both
ACTH secreting and non-ACTH secreting NETcells. A direct
antitumor action of ketoconazole may be an explanation for
prolonged remission of hypercortisolemia observed in some
patients with EAS and may have an added off target therapeu-
tic value next to its adrenal-suppressive effects. Additional
studies, including primary (ACTH-producing) NET cultures,
are required to confirm and further extend these results.
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